-
Rimonabant (also
known as SR141716;
trade names Acomplia, Zimulti) is an
anorectic antiobesity drug
approved in
Europe in 2006 but was
withdrawn worldwide...
-
receptor antagonists. The
first CBR
inverse agonist,
rimonabant, was
described in 1994.
Rimonabant blocks the CB1
receptor selectively and has been shown...
- at the CB1
cannabinoid receptor. AM-251 is
structurally very
close to
rimonabant; both are
biarylpyrazole cannabinoid receptor antagonists. In AM-251,...
-
oxaloacetate supplements had no
effect on
lifespan in
healthy laboratory mice.
Rimonabant (Acomplia) is an anti-obesity drug
initially approved for use in the European...
- were ever
approved by
specific jurisdictions. Some of them (lumiracoxib,
rimonabant, tolrestat, ximelagatran, and zimeldine, for example)
received marketing...
- The
antihypertensive effect of
spilanthol was
blocked by CB1
antagonist rimonabant and TRPV1
antagonist capsazepine,
suggesting spilanthol mediates some...
- cannabis),
increased appetite. However, some
drugs in this
class such as
rimonabant were
withdrawn or
ceased development to
concerns about mental health and...
-
cannabinoid receptor CB1. It is
derived from the
widely used CB1
antagonist rimonabant, and has
similar potency and
selectivity for the CB1 receptor, but has...
- depression, and
thoughts of
suicide in
patients treated with the now-withdrawn
rimonabant,
another CB1
antagonist that was also
under development by Sanofi-Aventis...
-
including flunarizine, mefloquine, and efavirenz.
Another notable agent is
rimonabant, a
cannabinoid receptor antagonist marketed as an anti-obesity
agent which...
